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Background
Policy-makers aim to achieve the partially conflicting
objectives of equitable access to medicines, cost contain-
ment and sustainable funding as well as reward for inno-
vation. To do so, a range of policy options is available that
has been extended in recent years to meet new challenges.
Objectives
To identify existing pharmaceutical reimbursement policy
options in European countries
Methods
A literature review was carried out using thesaurus and
free terms in several databases and grey literature. Setting:
Out-patient and in-patient sectors including possible mea-
sures at the interface of out-patient and in-patient sectors
and stakeholders involved: State (as regulator), third party
payers and patients (funders); pharmaceutical industry.
Inclusion criteria: Studies or documents published
between 1993 and February 2013 in all European Union
(EU) languages performed in all 28 EU Member States
and European Economic Area.
Results
In total 244 publications were selected, 61% of the selected
studies were published between 2007 and 2011. Most litera-
ture referred to a sole country, particularly to large countries
such as the UK and Germany. Descriptive work constituted
a major body of literature; an impact assessment of policy
measures was undertaken in 29% of the publications.
The five reimbursement policies most frequently men-
tioned were: co-payments (mentioned in 51% of the
selected publications); reimbursement rates (45%);
reference price systems (43%); positive lists (43%) and the
reimbursement process (40%). More than every sec-
ond publication addressed either HTA or pharmaco-
economics. Generic substitution, reimbursement reviews,
tendering and INN prescribing were identified in 35%–22%
of the included publications. Nine per cent of the publica-
tions referred to managed-entry agreements, and 7% men-
tioned value-based pricing. Reimbursement policies
addressed in low frequency were auction-like systems,
profit control or delisting from reimbursement.
Conclusions
Standard elements of reimbursement systems in European
countries were identified in several publications, whereas
newer policy options were covered less frequently in litera-
ture. Discussions about tools on how to best assess the
value of (new) medicines are recurring in literature.
The literature reflects, with some publication delay, the
approaches of policy-makers with regard to pharmaceuti-
cal reimbursement measures. In the 1990s and early years
of the new millennium, descriptive studies about national
reimbursement systems were predominant, supplemented,
at a later stage, by descriptions and analyses of generic
policies. In the new millennium, discussions about value
assessments and the importance of HTA and pharmaco-
economics, frequently understood as a contrast to the pri-
cing policy of external price referencing, were found.
Policy options for new, high-priced medicines were parti-
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